Evaluation of insulin binding and signaling activity of newly synthesized chromium(III) complexes in vitro

Molecular Medicine Reports

Volumn 3, Issue 2, 2010, Pages 347-353

  MacKowiak, Pawel ^a   Krejpcio, Zbigniew ^a   Sassek, MacIej ^a   Kaczmarek, Przemyslaw ^a   Hertirtig, Iwona ^a   Chmielewska, Joanna ^a   Wojciechowicz, Tatiaatiana ^a   Szczepankiewicz, Dawid ^a   Wieczorek, Daria ^b   Szymusiak, Henryk ^b   Nowak, Krzysztof W ^a  

^a POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^b POZNA UNIVERSITY OF ECONOMICS AND BUSINESS   (Poland)

Author keywords

Chromium(III) complexes; Insulin receptor; Insulin receptor substrate 1; Insulin signaling

Indexed keywords

ACETATE CHROMIUM; CHROMIUM DERIVATIVE; CHROMIUM GLYCINATE; CHROMIUM LACTATE; CHROMIUM PROPIONATE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; HORMONE BINDING; IMMUNODETECTION; IN VITRO STUDY; IN VIVO STUDY; INSULIN BINDING; INSULIN BLOOD LEVEL; LIVER MEMBRANE; MOUSE; MYOBLAST; NONHUMAN; PROADIPOCYTE; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

RATTUS;

EID: 77950822384     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_000000264     Document Type: Article

References (49)

1. Chan JM, Rimm EB, Colditz GA, Stampfer MJ and Willett W W C: Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17: 961-969, 1994.
2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
3. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104: 517-529, 2001.
4. Proietto J: Mechanisms of insulin resistance caused by nutrient toxicity. Hepatol Res 33: 87-91, 2005.
5. Kuryl T, Krejpcio Z, Wojciak RW, Lipko M, Debski B and Staniek H: Chromium(III) propionate and dietary fructans supplementation stimulate erythrocyte glucose uptake and beta-oxidation in lymphocytes of rats. Biol Trace Elem Res 114: 237-248, 2006.
6. Sahin K, Onderci M, Tuzcu M, et al: Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 56: 1233-1240, 2007.
7. Shinde UA, Sharma G, Xu YJ, Dhalla NS and Goyal RK: Anti-diabetic activity and mechanism of action of chromium chloride. Exp Clin Endocrinol Diabetes 112: 248-252, 2004.
8. Virkamaki A, Ueki K and Kahn CR: Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103: 931-943, 1999.
9. Mackowiak P, Nogowski L and Nowak KW : Comparison of erythrocyte insulin receptors in different species of vertebrates. Naturwissenschaften 79: 413-415, 1992.
10. Torlinska T, Mackowiak P, Nogowski L, Nowak KW , Madry E E and Perz M: Characteristics of insulin receptor binding to various rat tissues. J Physiol Pharmacol 49: 261-270, 1998.
11. Mackowiak P, Ginalska E, Nowak-Strojec E and Szkudelski T: The influence of hypo- and hyperthyreosis on insulin receptors and metabolism. Arch Physiol Biochem 107: 273-279, 1999.
12. Mackowiak P, Nogowski N and Nowak KW: High-carbohydrate and high protein diets alter liver and brain insulin receptors in rats. J Anim Feed Sci 2: 207-214, 1993.
13. Torlinska T, Mackowiak P, Nogowski L, et al: Age dependent changes of insulin receptors in rat tissues. J Physiol Pharmacol 51: 871-881, 2000.
14. Torlinska T, Perz M, Madry E, Hryniewiecki T, Nowak KW and Mackowiak P: Effect of hypothermia on insulin-receptor interaction in different rat tissues. Physiol Res 51: 261-266, 2002.
15. White MF: The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 53: 119-138, 1998.
16. Wilden PA, Kahn CR, Siddle K and White MF: Insulin receptor kinase domain autophosphorylation regulates receptor enzymatic function. J Biol Chem 267: 16660-16668, 1992.
17. Myers MG Jr and White MF: Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol Toxicol 36: 615-658, 1996.
18. Previs SF, Withers DJ, Ren JM, White MF and Shulman GI: Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 275: 38990-38994, 2000.
19. Withers DJ and White M: Perspective: the insulin signaling system - a common link in the pathogenesis of type 2 diabetes. Endocrinology 141: 1917-1921, 2000.
20. Carvalho CR, Brenelli SL, Silva AC, Nunes AL, Velloso LA and Saad MJ: Effect of aging on insulin receptor, insulin receptor substrate-1 and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology 137: 151-159, 1996.
21. Pederson TM, Kramer DL and Rondinone CM: Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50: 24-31, 2001.
22. Qiao LY, Goldberg JL, Russell JC and Sun XJ: Identification of enhanced serine kinase activity in insulin resistance. J Biol Chem 274: 10625-10632, 1999.
23. Saad MJ, Hartmann LG, de Carvalho DS, Galoro CA, Brenelli SL and Carvalho CR: Effect of glucagon on insulin receptor substrate-1 (IRS-1) phosphorylation and association with phosphatidylinositol 3-kinase (PI 3-kinase). FE FE BS Lett 370: 131-134, 1995.
24. Vincent JB: Elucidating a biological role for chromium at a molecular level. Acc Chem Res 33: 503-510, 2000.
25. Zick Y: Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE 2005: 4, 2005.
26. Hininger I, Benaraba R, Osman M, Faure H, Marie Roussel A and Anderson RA: Safety of trivalent chromium complexes: no evidence for DNA damage in human HaCaT keratinocytes. Free Radic Biol Med 42: 1759-1765, 2007.
27. Bagchi D, Stohs SJ, Downs BW, Bagchi M and Preuss HG: Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology 180: 5-22, 2002.
28. + do not cleave DNA under physiologically-relevant conditions. Polyhedron 18: 2617-2624, 1999.
29. Sun Y, Ramirez J, Woski SA and Vincent JB: The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. J Biol Inorg Chem 5: 129-136, 2000.
30. Vincent JB: Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc 63: 41-47, 2004.
31. Clodfelder BJ, Chang C and Vincent JB: Absorption of the biomimetic chromium cation triaqua-mu3-oxo-mu-hexapropionatotrichromium(III) in rats. Biol Trace Elem Res 98: 159-169, 2004.
32. Earnshaw A and Lewis J: Chemistry of polynuclear compounds. Part VI. Magnetic properties of trimeric chromium and iron carboxylates. J Chem Soc A: 1656-1663, 1966.
33. Wieczorek D, Staniek H, Krejpcio Z, Zielinski R and Szymusiak H: Synthesis and selected physicochemical properties of novel biomimetic complexes of chromium(III). I. Complexes with acetic and lactic acids. J Hum Nutr Metab 34: 1191-1196, 2007.
34. Wieloch A, Staniek H, Szymusiak H, Krejpcio Z and Zieliński R: Tricentric complexes of chromium(III) with glycine and serine ligands. Curr Trends Commod Sci 2: 1080-1086, 2007.
35. Wieloch D, Staniek H, Krejpcio Z, Szymusiak H and Zieliński R: Synthesis and selected physicochemical properties of novel biomimetic complexes of chromium(III). II. Complexes of chromium(iii) with alanine and glycine. J Hum Nutr Metab 34, 2007.
36. Havrankova J, Roth J and Brownstein M: Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272: 827-829, 1978.
37. Munson PJ and Rodbard D: Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239, 1980.
38. Gammeltoft S: Insulin receptors: binding kinetics and structure-function relationship of insulin. Physiol Rev 64: 1321-1378, 1984.
39. Shindea UA, Sharma G, Xu YJ, Dhalla NS and Goyal RK: Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. J Trace Elem Med Biol 18: 23-32, 2004.
40. Broadhurst CL and Domenico P: Clinical studies on chromium picolinate supplementation in diabetes mellitus - a review. Diabetes Technol Ther 8: 677-687, 2006.
41. Martin J, Wang ZQ, Zhang XH, et al: Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29: 1826-1832, 2006. (Pubitemid 44156637)
42. Ward C, Lawrence M, Streltsov V, et al: Structural insights into ligand-induced activation of the insulin receptor. Acta Physiol 192: 3-9, 2008.
43. Chen G, Liu P, Pattar GR, et al: Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 20: 857-870, 2006.
44. Wang ZQ, Zhang XH, Russell JC, Hulver M and Cefalu WT: Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 136: 415-420, 2006.
45. Bunting LD, Tarifa TA, Crochet BT, Fernandez JM, Depew CL and Lovejoy JC: Effects of dietary inclusion of chromium propionate and calcium propionate on glucose disposal and gastrointestinal development in dairy calves. J Dairy Sci 83: 2491-2498, 2000.
46. Muller G, Jung C, Wied S, Welte S, Jordan H and Frick W: Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes. Mol Cell Biol 21: 4553-4567, 2001.
47. Pattar GR, Tackett L, Liu P and Elmendorf JS: Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 610: 93-100, 2006.
48. Brautigan DL, Kruszewski A and Wang H: Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes. Biochem Biophys Res Commun 347: 769-773, 2006.
49. 49.Yang X, Palanichamy K, Ontko AC, et al: A newly synthetic chromium complex - chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 579: 1458-1464, 2005.